COMPASS Pathways : investor presentation May 2025
CMPS
Published on 05/09/2025 at 09:33
Investor Presentation
May 2025
Dedicated toacceleratingpatient accesstoevidence-based
innovationinmental health
Lead product candidate: COMP360 psilocybin treatment in treatment resistant depression (TRD)
Phase 2 TRD program published in The New England Journal of Medicine
Phase 3 TRD program recruiting
Pivotal trial 1 (COMP005): top-line 6-week data expected late June
Pivotal trial 2 (COMP006): 26-week data expected H2 2026
Phase 2 PTSD positive top-line data reported in Q2 2024, late stage clinical
study in development
Cash position of $260.1 million at March 31, 2025
3 | © Compass Pathways
~21M
~10M
~3M
Treatment-resistant depression (TRD) is broadly referred to as the inadequate response to at least 2 trials of antidepressant pharmacotherapy1
1) Voineskos 2020; 2) National Institute of Mental Health. Major Depression. 2022; 3) NIMH 2019; 4) Zhdanava 2019
4 | © Compass Pathways
Condition
Major Depressive Disorder (MDD)
Treatment Resistant Depression
(TRD)
Treatment Line of
Therapy
1st Line
2nd Line
3rd Line+
Typical treatment progression and available treatments
Pharmacotherapy:
Traditional antidepressant
Dose escalation of current
antidepressant
Pharmacotherapy:
Switch to different traditional
antidepressant
Add a traditional antidepressant
Pharmacotherapy:
Switch to a different traditional
antidepressant
Add a traditional antidepressant
Augmentation therapy (antidepressant + mood stabilizers, anticonvulsants, atypical antipsychotics)
Spravato (esketamine)
Somatic therapy (rTMS, tDCS,
ECT, DBS)*
*NOTE: rTMS = repetitive transcranial magnetic stimulation; tDCS=transcranial direct current stimulation; ECT=electroconvulsive therapy; DBS=deep brain stimulation
5 | © Compass Pathways
Disclaimer
Compass Pathways plc published this content on May 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 09, 2025 at 13:26 UTC.